For tumours with an activating EGFR mutation, first‐line treatment with an EGFR tyrosine kinase inhibitor (gefitinib, erlotinib, afatinib, dacomitinib, and orosimertinib) is recommended, with ALK inhibitors (crizotinib, alectinib, ceritinib, and brigatinib) preferred for patients with ALK‐rearranged NSCLC (NCCN, 2018; Planchard et al., 2018). This evidence concerns the gene ALK and non-small cell lung carcinoma.